論文・技術情報追加のお知らせ

1. Analysis of Upper Gastrointestinal Adverse Events Associated with Oral Anticoagulants and Potential Drug Interactions with Cardiovascular Drugs: Exploratory Study Using FDA Adverse Event Reporting System.

OACでUGIリスク薬別差、CV併用で交互作用示唆

対象DB：FAERS,KAERS

2. Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).

チルゼパチドで投与誤り激増、消化器・注射部位AE目立つ

対象DB：FAERS

3. Rapid Screening of Anticoagulation Compounds for Biological Target-Associated Adverse Effects Using a Deep-Learning Framework in the Management of Atrial Fibrillation.

深層学習でAF薬有害事象を予測、性能良好

対象DB：FAERS

4. FAERS based disproportionality analysis and network pharmacology investigation of doxorubicin associated drug induced cardiotoxicity.

リポ製剤で心筋症等リスク低下も重篤性同程度

対象DB：FAERS

5. Detection and warning of drug-induced hypomagnesemia: a pharmacovigilance study of the FDA Adverse Event Reporting System.

低Mg血症シグナル多数、PPI・抗EGFR抗体で強

対象DB：FAERS

6. Thromboembolic events associated with angiogenesis inhibitors: a real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.

血管新生阻害薬でTEEs強シグナル・早期発生傾向

対象DB：FAERS

7. A disproportionality analysis of insulin glargine in the overall population and in pregnant women using the FDA adverse event reporting system (FAERS) database.

インスリンGで低血糖中心の強シグナル、妊婦で遅発傾向

対象DB：FAERS

8. Differences in Safety Signal Detection Between Osimertinib and First- and Second-Generation EGFR-TKIs: A Pharmacovigilance Study Using a Spontaneous Reporting System.

オシメルチニブで心毒性・骨髄抑制シグナル強

対象DB：FAERS,JADER

9. DrugCombo: an informatics bridge for anticancer drug combination Phase I trial design.

DrugCombo統合毒性DBで第I相設計支援

対象DB：FAERS

10. Real-world large sample evaluation of drug-related blepharoptosis: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database.

眼瞼下垂の薬剤シグナルをFAERSで網羅評価

対象DB：FAERS

11. The Association Between Stimulant Medication Use and Mortality.

刺激薬で突然死・死亡リスク増大示唆

対象DB：FAERS

12. Artificial intelligence-driven pharmacovigilance analysis of polypharmacy and adverse events in breast cancer survivors treated with antidepressants.

乳癌生存者の多剤併用で群別安全性シグナル確認

対象DB：FAERS

13. Post-Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System.

ビメキズマブ後販安全性をFAERSで解析

対象DB：FAERS

14. Ranking the Diabetes-related Safety Profile of Different Statin Drugs.

アトルバ高糖尿病リスク、他スタチン差あり

対象DB：FAERS

15. Drug-drug interactions: A descriptive analysis of FDA adverse event reporting system.

FAERSでDDI多数、重篤・死亡報告含む

対象DB：FAERS

16. Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system.

ソルリアムフェトルで精神神経・心疾患AE多発

対象DB：FAERS

17. Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System.

BLIで多彩AEシグナル、アビ/レレで死亡増加傾向

対象DB：FAERS

18. Do PCSK9 Inhibitors Impair Memory? A Dual Approach Combining Real-World Data and Genetic Evidence.

PCSK9阻害薬で記憶障害因果なし示唆

対象DB：FAERS

19. Linezolid-related Optic Nerve Disorders: Insight From a Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System.

リネゾリドで視神経障害シグナル、若年・高累積量で高リスク

対象DB：FAERS

20. Post-Marketing Safety Concerns with Efgartigimod alfa: A Pharmacovigilance Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database.

EAで多系統AEシグナル、球麻痺等早期注意

対象DB：FAERS

21. Integrative analysis of levofloxacin-induced liver injury: Insights from pharmacovigilance, human liver organoids, and extracellular vesicle proteomics.

LVXで胆汁性DILI信号、解糖系再プログラム関与

対象DB：FAERS

22. Drug-induced cough risk: A pharmacovigilance study of FDA adverse event reporting system database.

多薬剤で咳リスク把握、抗TNF等で多発

対象DB：FAERS

23. Exploring Definity-related adverse reaction: A real-world pharmacovigilance study via FAERS database analysis.

デフィニティで過敏症・心肺反応のシグナル検出

対象DB：FAERS

24. Progressive multifocal leukoencephalopathy reports in rheumatoid arthritis concerning different treatment patterns-an exploratory assessment using the food and drug administration adverse event reporting system.

MTX＋リツキシマブでPML報告増、男性高齢で高リスク

対象DB：FAERS

25. Influence of differential source patterns in the detection of signals of disproportionate reporting for PARP inhibitors.

報告源の偏りがSDR検出に影響、検証必要

対象DB：JADER,VigiBase

26. Real-World Safety Characteristic of Iguratimod: A Pharmacovigilance Study Based on the Japanese Adverse Drug Event Report (JADER) Database.

イグラチモドで肺障害等多数、初期3ヶ月要警戒

対象DB：JADER

27. Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database.

患者報告はQOL症状重視で専門家報告を補完

対象DB：JADER

28. Hepatotoxicity and Antimicrobial Resistance to Amoxicillin and Amoxicillin/Clavulanic Acid: Data Analysis from EudraVigilance.

アモクラで肝障害・耐性のシグナル増加確認

対象DB：EudraVigilance

29. Pharmacovigilance Insights into Ibuprofen's Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports.

イブプロフェンでNPシグナル高く、OTCゆえ注意必要

対象DB：EudraVigilance

30. Real-World Evidence of Neuropsychiatric Adverse Reactions to Isotretinoin: Insights from EudraVigilance (2005-2025).

イソトレチノインでNPsRsのシグナル持続、若年で顕著

対象DB：EudraVigilance

31. Serious Adverse Drug Reactions to COVID-19 Vaccines in the Pediatric Population: A Retrospective, Cross-Sectional Study Utilizing the Eudravigilance Database for the European Economic Area.

小児COVID-19ワクチンSADR稀、2剤で類似リスク構成

対象DB：EudraVigilance

32. Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation.

オビヌツズマブで非顕性DICシグナル確認・添文更新

対象DB：EudraVigilance

33. Charting and Sidestepping the Pitfalls of Disproportionality Analysis.

DPAは補助的手法、偏り回避が重要

対象DB：VigiBase

34. Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination.

併用で新規毒性なしも血栓致死率上昇に注意

対象DB：VigiBase

35. Adverse events of antibody-drug conjugates: Comparative analysis of agents with a common payload using the adverse event spontaneous reporting database.

同ペイロードADCでPN・骨髄抑制共通、差異あり

対象DB：JADER

36. Association Between Kounis Syndrome and Allergy-Associated Coronary Events: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database.

KS非診断例は重症背景・高致死で過少認識懸念

対象DB：JADER

37. Factors Influencing the Availability of Cardiopulmonary Exercise Testing for Patients Undergoing Cardiac Resynchronization Therapy in Japan.

CRT後のCPET実施率低、若年・高BI・心リハで増加

対象DB：DPC

38. Timing of rehabilitation and pressure ulcers requiring treatment during acute hospitalization in patients with cervical spinal cord injuries.

早期リハで褥瘡差なし、入院期間短縮傾向

対象DB：DPC

39. Outcomes of continuous kidney replacement therapy versus intermittent hemodialysis in dialysis-dependent patients with acute intracerebral hemorrhage.

連続/間欠透析で院内死亡・機能転帰差なし

対象DB：DPC

40. Trends in the use of Japanese herbal Kampo medicine in inpatients with cancer: a 14-year nationwide analysis.

漢方はがん入院で支援的に増減・高齢者多用

対象DB：DPC

41. Association between Orthotic Intervention and Reamputation after Minor Lower Extremity Amputation in Patients with Vascular or Systemic Disease: A Nationwide Administrative Database Study in Japan.

装具介入で同側再切断・死亡が低減、因果不明

対象DB：DPC

42. Evaluation of inhalation device prescribing trends: A retrospective database study in Japan.

日本で吸入療法は併用・新機種へ移行、年齢性差あり

対象DB：NDB

43. Treatment patterns, outcomes, healthcare resource utilization, and costs associated with locally advanced squamous cell carcinoma of the head and neck in Japan.

日本LA-SCCHNで非手術/手術多、入院負担大・未治療も多い

対象DB：MDV

44. Ethnic disparities in opioid prescribing for cancer pain and associated emergency department visits and hospital admissions in the last three months of life: a retrospective cohort study.

少数民族で終末期オピオイド少・救急入院多

対象DB：CPRD

45. Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate/Vilanterol or Beclometasone Dipropionate/Formoterol Fumarate in General Practice in England.

全体は同等、12ヶ月継続でFF/VI優位

対象DB：CPRD

46. Effect of leukotriene receptor antagonist use on the future risk of Parkinson's disease in older patients with asthma.

LTRAでPDリスク不変、抑うつ・睡眠障害増加

対象DB：CPRD

47. Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study.

薬剤不足で使用減少と適応・用量変化発生

対象DB：CPRD

48. Non-adherence to medications prescribed to patients with heart failure in general practice: prevalence, risk factors and association with mortality and hospitalisation.

HF薬物非遵守は高率で予後不良、介入要

対象DB：CPRD

49. Pre-Diagnostic Features of Multiple Sclerosis in a Diverse UK Cohort: A Nested Case-Control Study.

MS診断前症状は一貫して増加、層差なし

対象DB：CPRD

50. Performance of the EndPAC risk score for pancreatic cancer in new onset diabetes patients with missing data - a database study in the British population.

欠測補完でEndPAC適用可、単独では不十分

対象DB：CPRD

51. The independent and combined effects of smoking and chronic obstructive pulmonary disease on body mass index trajectories.

COPDでも喫煙がBMI低下を加速、禁煙で増加

対象DB：THIN

52. [Risk of mucocutaneous ulcerations associated with nicorandil: Recent data of the French Pharmacovigilance DataBase and Toulouse Hospital Discharge DataBase (NICORUC)].

ニコランジル潰瘍AEは持続、早期中止が重要

対象DB：FPVD

53. Enhancing adverse drug reaction data quality in Canada: A high-precision pipeline for medication name standardization and enrichment.

薬剤名標準化でADR検出感度向上、精度高い

対象DB：CVAR

54. Constipation and Incident Cardiovascular Disease: A Nationwide, Real-World Cohort Study.

便秘はCVD発症リスク増、予測改善に寄与

対象DB：DeSC

55. Cardiovascular-kidney-metabolic syndrome stage predicts cardiovascular outcomes in cancer patients: a real-world data analysis of a nationwide epidemiological dataset.

CKM高ステージほどがん患者のCVDリスク増大

対象DB：DeSC

56. Sodium-glucose co-transporter-2 inhibitors vs metformin in reducing osteoarthritis risk: a retrospective cohort study of health insurance claims and check-up data.

SGLT2iとメトでOA発症率に有意差なし

対象DB：DeSC

57. Population-based claims study of regional and hospital function differences in opioid prescribing for cancer patients who died in hospital in Japan.

地域・病院でオピオイド使用差、均質化課題あり

対象DB：DeSC

58. Trends in Nonsurgical Interventions and Analgesic Medications for Low Back Pain: A Large Claims Database Study in Japan.

慢性腰痛で非手術介入増、NSAIDs・オピ減少傾向

対象DB：DeSC